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The Abelson helper integration site 1 (AHI1) gene locus on chromosome 6q23 is among a group of candidate
loci for schizophrenia susceptibility that were initially identified by linkage followed by linkage disequilibrium
mapping, and subsequent replication of the association in an independent sample. Here, we present results
of a replication study of AHI1 locus markers, previously implicated in schizophrenia, in a large European
sample (in total 3907 affected and 7429 controls). Furthermore, we perform a meta-analysis of the implicated
markers in 4496 affected and 18 920 controls. Both the replication study of new samples and the meta-analy-
sis show evidence for significant overrepresentation of all tested alleles in patients compared with controls
(meta-analysis; P 5 8.2 3 1025 –1.7 3 1023, common OR 5 1.09–1.11). The region contains two genes,
AHI1and C6orf217, and both genes—as well as the neighbouring phosphodiesterase 7B (PDE7B)—may be
considered candidates for involvement in the genetic aetiology of schizophrenia.
INTRODUCTION
Schizophrenia is a common mental disorder affecting 0.5–1%
of the population and is the seventh most costly medical
illness to western societies (1). Psychosis has been ranked
the third-most-disabling condition, after quadriplegia and
dementia (2), and life expectancy is reduced by approximately
15–20%, due to increased physical health problems and a high
suicide rate (3,4). Family, twin and adoption studies show evi-
dence for a strong genetic component in schizophrenia, and
the relative contribution of genetic factors has been estimated
to be at least 65% (5). Despite this high heritability, only a
very limited number of putative susceptibility genes have
been replicated to date (6).
Association of AHI1 with schizophrenia was first reported
in an inbred Israeli Arab family sample with high incidence
of schizophrenia through a genome-wide linkage scan (7), a
refined linkage analysis of a linkage peak on 6q (8) and a sub-
sequent fine-mapping study that identified seven markers sig-
nificantly associating with schizophrenia after correction for
multiple testing (9). All seven markers reside within an
extended block of high linkage disequilibrium (LD), also har-
bouring the C6orf217 gene and a predicted micro-RNA gene
(MIR548H4). The findings were subsequently replicated in
an independent Icelandic case–control sample (10). The 6q
region has been linked to schizophrenia in other studies as
well (11–13), but possible association with AHI1 markers
was not addressed in those samples. Furthermore, other
common variants within the AHI1 locus have recently been
reported to associate with autism in a candidate gene study
(14). This is a notable observation given the recent discoveries
of rare genomic microdeletions associated with psychosis on
chromosomes 1q21.1, 15q11.2, 15q13.3 (15,16) and 2p16.3
(17,18) that have also been identified in other neurodevelop-
mental disorders including autism (19,20) and mental retar-
dation (21,22).
Loss-of-function mutations in the AHI1 gene cause Joubert
syndrome (OMIM: 213300), an autosomal recessive, cerebel-
lar and cortical neurodevelopmental disorder marked by agen-
esis of the cerebellar vermis; ataxia; hypotonia; oculomotor
apraxia; and various motor, cognitive and behavioural disturb-
ances, including mental retardation (23–26). The AHI1 gene
encodes the protein Jouberin which contains seven WD40
repeats, an SH3 domain, potential SH3 binding sites and an N-
terminal coiled-coil domain (27). AHI1 is widely expressed
in the brain and comparative analysis of the AHI1 locus in
primates indicates that the gene has undergone positive selec-
tion during the evolution of the human lineage (23). Moreover,
expression studies of AHI1 orthologues in mouse (23,24,28)
and zebrafish (28) suggest a conserved role of Jouberin in neu-
rodevelopment. The mouse orthologue of Jouberin, Ahi1,
binds to huntingtin-associated protein 1 (Hap1) to form a
stable protein complex in the brain that is important for main-
taining the level of tyrosine kinase receptor B (TrkB), which is
critical for neuronal differentiation and brain development
(29). Interestingly, the endogenous TrkB ligand in humans—
brain derived neurotrophic factor (BDNF)—is a survival
factor for parvalbumine-positive interneurons, which have
been shown to be specifically altered in a series of post-
mortem studies in schizophrenia, and are thought to be
involved in the pathobiology of this disorder (30).
Here, we present results of a replication study of seven
AHI1 locus markers, previously implicated in schizophrenia
(9,10), in a large European sample (in total 3907 affected
and 7429 controls). Furthermore, we perform a meta-analysis
of the implicated markers in a total sample of 4496 affected
patients and 18 920 controls.
RESULTS
A summary of the number of patients and controls in each
replication subgroup and the use of surrogate marker alleles
(see Materials and Methods) is provided in Table 1 and Sup-
plementary Material, Table S1, respectively, while the allele
counts for each marker in each replication subgroup are
given in Supplementary Material, Table S2. The distribution
of genotypes of all tested markers was consistent with
Hardy–Weinberg proportions in all samples after correction
for multiple testing (Supplementary Material, Table S3).
The combined analysis of all new replication samples—
Munich, SCOPE, SGENEþ (excluding the previously
reported Icelandic replication sample) and Cardiff—showed
that all seven alleles were over-represented in affected com-
pared with controls (Table 2). The association remained sig-
nificant for six alleles using a conservative Bonferroni
correction for seven tests, but considering the high LD
between many of the markers [rs11154801, rs7750586 and
rs9647635 are roughly equivalent; and rs7739635, rs9494332
and rs1475069 are highly inter-correlated (r2. 0.7)], the
number of independent tests is more likely to lie between
three and five, in which case all seven alleles remain significant.
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When we include the Icelandic part of the SGENEþ sample in
the analysis, the association is stronger (Table 2) and all seven
alleles are significant even with the conservative Bonferroni
correction (corrected P ¼ 0.00057–0.012). A Woolf’s test of
homogeneity of odds ratios across subgroups was non-
significant for all markers, i.e. the distribution of odds ratios
across subgroups for each marker is compatible with that
expected given a common odds ratio. The distribution of
odds ratios with 95% confidence intervals along with the
results of the Woolf’s tests is shown in Figure 1. An explora-
tory analysis of the SGENEþ samples, using the Illumina
HumanHap300 marker set and the SNPTEST imputation
program (http://www.stats.ox.ac.uk/marchini/software/
gwas/snptest.html), found no imputed HapMap marker in the
locus among those markers polymorphic in the CEU
HapMap population (Phase II) showing significantly stronger
association with illness than rs1475069 (data not shown).
Similarly, an analysis of all haplotype combinations between
the five surrogate markers in the SGENEþ sample, using
the NEMO (31) algorithm, found no haplotype with signifi-
cantly stronger association with illness than rs1475069 (data
not shown).
DISCUSSION
The AHI1 locus was first implicated in genetic schizophrenia
susceptibility in a family sample of Israeli Arabs using the
classical gene identification approach of positional cloning
(7–9). This finding was replicated in an Icelandic case–
control study (10). Here, we have provided further support
for association in a second replication study, and combined
the results with those of the previous replication study
(adding additional Icelandic controls) into a powerful
meta-analysis of the implicated AHI1 markers including data
from 4496 affected and 18 920 controls. The combined
results reveal association of all seven tested alleles with
increased risk of schizophrenia. The meta-analysis includes
the previously reported Icelandic replication sample (10) (as
part of the SGENEþ sample), but not the discovery Israeli
Arab family sample (9), and should therefore avoid the
‘winner’s curse’.
Consistent with the approaches now in use in follow-up
studies of genome-wide association data sets (32–34), we
have used a one-sided test for analyses that exclude the
initial discovery sample. Thus, we specifically test the hypoth-
esis that the alleles that were over-transmitted to affected off-
spring in the discovery family sample (9) have an increased
frequency in affected compared with control individuals in
replication samples. The current study originates in the
direct genotyping of the previously associated AHI1 markers
(or perfect surrogates thereof) in the German Munich sample
and the Danish/Norwegian SCOPE sample. Genotype counts
for these markers or the closest available surrogate markers
(in terms of correlation) were then obtained from genome-
wide genotyped samples from collaborating researchers
(SGENEþ and Cardiff) and all results combined into a
Cochrane–Mantel–Haentzel analysis (as described in
Materials and Methods) to estimate the allele frequencies of
these markers in affected versus controls across all samples.
The researcher responsible for conducting the association
analysis was thus blinded to the SGENEþ and Cardiff geno-
types of the involved markers prior to contacting researchers
from these groups, and remains blinded to other genotypes
from these samples. Accordingly, we correct only for seven
tests in our interpretation of the significance of the result.
This approach is in compliance with the guidelines presented
in a recent article on replication studies of genotype–pheno-
type associations (35).
The use of surrogate markers in a meta-analysis under the
assumption of equal odds ratios may be questionable, as it
could underestimate the real odds ratios of the original
seven markers. However, by the logic of LD mapping, the
original seven markers may not necessarily be the true
at-risk markers in the locus, but merely surrogates thereof.
Thereby, the surrogate markers may provide as good or even
better estimate than the original markers themselves, of
the risk conferred by the true at-risk variation in the locus.
Table 2. Association results from a combined Cochrane–Mantel–Haentzel
analysis
Allelea New replication samplesb All replication samplesc
P-value OR (95%CI) P-value OR (95%CI)
rs9321501-A 5.1  1023 1.08 (1.02–
1.15)
4.9  1024 1.09 (1.04–
1.15)
rs11154801-C 6.6  1023 1.08 (1.02–
1.15)
1.6  1023 1.09 (1.03–
1.15)
rs7750586-A 6.6  1023 1.08 (1.02–
1.15)
1.7  1023 1.09 (1.03–
1.15)
rs9647635-A 6.7  1023 1.08 (1.02–
1.15)
1.7  1023 1.09 (1.03–
1.15)
rs7739635-C 2.8  1023 1.09 (1.03–
1.16)
8.2  1025 1.11 (1.05–
1.18)
rs9494332-A 3.0  1023 1.09 (1.03–
1.17)
2.4  1024 1.11 (1.05–
1.17)
rs1475069-A 9.7  1023 1.08 (1.01–
1.15)
2.3  1024 1.11 (1.05–
1.17)
The details of subsamples, surrogate markers and allele counts are provided in
Supplementary Material, Table S2.
aOvertransmitted to affected in Amann-Zalcenstein et al. (9).
bMunich, SCOPE, SGENEþ (excluding Icelandic part) and Cardiff samples.
cAll new samples and the Icelandic part of SGENEþ.
Table 1. Number of patients and controls in different replication samples
Study Sample Patients Controls
Munich German 495 1272
SCOPE Danish 456 995
SCOPE Norwegian 264 181
SGENEþ Icelandic 589a 11 491
SGENEþ Finnish General population 59 147
SGENEþ Finnish Genetic isolate 123 50
SGENEþ Italian 84 89
SGENEþ British 93 88
SGENEþ Scottish 658 661
SGENEþ German (Bonn) 483 367
SGENEþ Dutch 713 643
Cardiff British 479 2936
Total – 4496 18 920
aEssentially the same patients as reported in Ingason et al. (10).
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Furthermore, the results of the Woolf’s test show that for each
marker the distribution of odds ratios across subgroups is com-
patible with the assumption of a common odds ratio (Fig. 1).
In any case, the use of surrogates in this manner is unlikely
to inflate the estimate of the true disease risk conferred by
genetic variation within the locus.
Figure 1. The distribution of odds ratios across subgroups for five of the seven tested alleles at the AHI1 locus, along with the number of affected and control
individuals for each subgroup, and the results of Woolf’s test of homogeneity of odds ratios. Results for alleles rs7750586-A and rs9647635-A are not included as
they are roughly equivalent to those for rs11154801-C.
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By applying a Cochrane–Mantel–Haentzel analysis, we
compare each sub-sample separately. This is necessary for
two reasons; first, because we use data from different popu-
lations (allele frequencies of common variants often vary
between populations); and second, because samples are geno-
typed for different surrogate markers that also have subtle
differences in allele frequencies. It could seem feasible to
pool all the samples into one, since they are all of European
origin, but in this case both abovementioned factors would
create a bias in the results as the patient-to-control ratios
vary substantially between sub-samples.
As mentioned in the first paragraph of this section, the Ice-
landic patients of the SGENEþ sample are essentially the
same as from our previous study (10), while the Icelandic
SGENEþ control group is much larger than that of the pre-
vious study. We therefore decided to use the Icelandic
SGENEþ results in the meta-analysis rather than the results
of our earlier study. Either way, we feel justified to include
the Icelandic sample in the meta-analysis as the previously
reported Icelandic study was a replication study and not one
of gene discovery. Also, while the association for the seven
markers tested here is individually significant in both our
meta-analysis of case–control samples and the family-based
association study by Amann-Zalcenstein et al. (9), it is of
interest to calculate the combined probability of the results
of both studies. By applying Fisher’s combined probability
test, we estimate the two-sided probability for no association
given the results of both studies to range from 2  1028 for
rs7739635 and rs1475069 to 1  1025 for rs7750586 (with
4  1028, 3  1027, 1  1026 and 2  1026 for rs11154801,
rs9494332, rs9647635 and rs9521501, respectively).
The biology of the AHI1 gene makes it a plausible candidate
for involvement in schizophrenia aetiology. As mentioned
earlier, it is widely expressed in brain and appears to partici-
pate in cellular processes important for early development of
the brain. The association seen by Alvarez Retuerto et al.
(14) between AHI1 markers and autism is also interesting, as
there is known phenotypic and perhaps also aetiological
overlap between autism and schizophrenia. The most signifi-
cantly overtransmitted haplotype of Alvarez Retuerto et al.
(14) is tagged by the C allele of rs17707754. The imputation
results of the SGENEþ data set using SNPTEST suggest
that this allele is over-represented in cases (P ¼ 0.003,
common OR ¼ 1.72), but the relative statistical information
is low (29%) due to poor tagging information for
rs17707754 in the HumanHap300 marker set, and therefore
the result has to be interpreted with caution.
The LD structure, arrangement of known genes, and markers
typed in this study are shown in Figure 2. The genes include—
in addition to AHI1—C6orf217 and PDE7B as well as the pre-
dicted micro-RNA gene MIR548H4. C6orf217 is expressed in
brain, but its function remains unknown. Phosphodiesterase
7B is highly expressed in brain and thought to be involved
in the control of cAMP-mediated neural activity and cAMP
metabolism in the brain (36), and in the striatum, PDE7B tran-
scription is activated by dopamine receptor D1 signalling
mediated through the cAMP/cAMP-dependent protein
kinase/cAMP-response element binding protein pathway
(37). Although the LD block containing the markers tested
here does not extend into PDE7B itself, regulatory elements
affecting its transcription may be embedded in the sequence
upstream of the gene, and thus be in LD with the markers
tested here (Fig. 1). It should though be emphasized that the
existence of such elements is entirely speculative at present.
We observe low odds ratios for the associated markers
(1.09–1.11); this is not unexpected as it has been widely
established through genome-wide association studies
(GWAS) of common disease, that more often than not, the
risk conferred by truly associating variants is indeed modest.
For example, the marker rs1344706 was recently identified
as associating with schizophrenia and bipolar disorder follow-
ing a three-phased GWAS, with a common odds ratio of 1.12
derived from the combined samples (38). This association was
subsequently replicated with similar odds ratios in two studies
(39,40). Similar odds ratios are also seen for genome-wide sig-
nificantly associating markers that have recently been ident-
ified in three large genome-wide studies in schizophrenia
(41–43). It is believed that genetic variants associated with
such subtle disease risk, interact with other susceptibility var-
iants, as well as environmental factors in precipitating disease
onset. Bearing this in mind, the recent discovery of a linkage
region on chromosome 10 interacting with the linkage region
of 6q23 (44) in the same Israeli Arab families wherein AHI1
association to schizophrenia was first described (9), may
provide a hint for further studies seeking genetic variants inter-
acting with AHI1 variants to increase schizophrenia risk.
In conclusion, we have found convincing evidence for
association of common variation in the 6q23 region around
AHI1, C6orf217 and PDE7B with schizophrenia in a large
European case–control sample. This evidence further consoli-
dates the locus as one of the few established genetic loci har-
bouring common schizophrenia risk variants.
MATERIALS AND METHODS
Samples and genotyping
Munich. The Munich sample included 495 schizophrenia
patients and 1272 healthy controls from Munich, Germany.
Six out of seven markers from the previous studies were
tested in this sample; the assay for rs7739635 failed and a sur-
rogate marker, rs12196952 (r2 ¼ 0.85 in HapMap CEU trios),
was typed instead. The Munich sample was genotyped at
the Genetics Research Centre GmbH in Munich, Germany.
One nanogram of DNA was assayed using the iPLEX assay
on the MassARRAY MALDI-TOF mass spectrometer
(SEQUENOM, Hamburg, Germany). DNA concentration
was adjusted using the PicoGreen quantitation reagent
(Invitrogen, Karlsruhe, Germany).
SCOPE. The SCOPE sample included 456 and 264 patients
affected with schizophrenia or related psychoses, and 995
and 181 healthy controls from Denmark and Norway, respect-
ively. Four out of the seven markers from previous studies
were tested in the SCOPE sample; markers rs11154801 and
rs9647635 were not typed due to very high LD with
rs7750586 (r2 ¼ 0.96 and 1, respectively, in HapMap CEU
trios); the surrogate markers rs9494335 and rs9399158 were
used for markers rs9494332 and rs1475069, respectively [as
in Ingason et al. (10), r2 ¼ 1 in HapMap CEU trios in both
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cases]; and the assay for rs7739635 failed. The SCOPE sample
was genotyped at deCODE Genetics using the Centaurus plat-
form (Nanogen Inc., San Diego, CA, USA).
SGENEþ. The SGENEþ sample studied here includes 2802
patients affected with schizophrenia or related psychoses
and 13 536 control individuals from Iceland, Scotland,
Germany, UK, Italy, Finland and the Netherlands. The Icelan-
dic patients of the SGENEþ sample are essentially the same
as reported in the previous replication study (10), but the Ice-
landic SGENEþ control group is much larger than the one
previously reported. Therefore, while we omit the Icelandic
samples altogether from the analysis of new samples, we
use the results from the Icelandic SGENEþ sample (rather
than those previously reported) in the meta-analysis of all
replication samples. The core SGENE sample was genotyped
on the HumanHap300 BeadArrayTM at deCODE genetics.
The additional SGENEþ samples from Aberdeen were geno-
typed, respectively, on the HumanHap550v2 BeadArrayTM
(Illumina, San Diego, CA, USA), at Duke University in col-
laboration with GlaxoSmithKline. The SGENEþ samples
from Germany and the Netherlands were genotyped on the
HumanHap550v3 BeadArrayTM (Illumina, San Diego, CA,
USA) at Bonn University and UCLA, respectively. In the
SGENEþ sample only subjects with at least 98% genotype
yield (on the entire micro-array) were used in the association
analysis.
Cardiff. The Cardiff sample included 479 schizophrenia
patients and 2936 controls from the UK. The patient sample
was genotyped on the Affymetrix GeneChip 500K Mapping
Array as part of the Wellcome Trust Case-Control Consortium
pipeline (though it was not part of that study), and the control
genotypes are those reported by the WTCCC (45).
Ethical approval was obtained from the local Ethics Com-
mittees. All participants gave written informed consent. A
summary of the sample sizes is given in Table 1, while a more
Figure 2. View of markers, genes and LD structure at the AHI1 locus using the UCSC Genome Browser (http://genome.ucsc.edu). The markers genotyped in
different sub-samples to assess association of markers from the original family association study (9) are shown at top, followed by a track showing genes from the
RefSeq database. Linkage disequilibrium (r2) in the HapMap CEU population (http://www.hapmap.org) is shown at bottom. Genomic coordinates are according
to NCBI genome build 36.
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detailed sample description is provided in Supplementary
Material online.
Association analysis
We performed a combined analysis using a one-sided exact
Cochrane–Mantel–Haentzel test for enrichment of the over-
transmitted alleles in patients. In this analysis, allele frequen-
cies in patients and controls are compared separately for each
sub-sample and a common odds ratio derived for all sub-
samples (i.e. it is assumed that odds ratios calculated for
each sub-sample are distributed around a common ‘true’
odds ratio). We assumed that odds ratios of surrogate alleles
are the same as those of the alleles of the original study (9).
Markers rs12196952 and rs9494335 served as surrogates for
rs7739635 in the Munich and SCOPE samples, respectively,
and rs7750586 for rs1154801 and rs9647635 in the SCOPE
sample only. In the SGENEþ samples, surrogate markers on
Illumina micro-arrays were used for the five markers not
present on the arrays. In the Cardiff sample, surrogate
markers on the Affymetrix GeneChip 500K Mapping Array
were used for the six markers not present on the array. A
summary of the surrogate alleles used in the current study to
assess association of the markers implicated from previous
studies showing marker correlations derived from the
HapMap CEU sample (available at http://www.hapmap.org)
is provided in Supplementary Material, Table S1. A Woolf’s
test was performed to estimate homogeneity of odds ratios
across subgroups in the Cochrane–Mantel–Haentzel
meta-analysis. Because all the tested markers are in LD,
most missing genotypes could be imputed from genotypes at
other marker loci through a likelihood approach implemented
in the program NEMO (31). Inclusion of this partial infor-
mation allowed findings for each marker to be better compar-
able, as they were based on the same set of individuals.
Although P-values in the meta-analysis are one-sided, the
95% confidence intervals for common odds ratios are
derived from a two-sided alternative hypothesis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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